All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityABBs-Block Trades

Synairgen raises £80m after Covid-19 treatment shows progress


Synairgen, the UK biopharmaceuticals company, has raised £80m from investors to fund the next stage of clinical trials for a treatment designed to alleviate the respiratory symptoms of Covid-19.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree